ClinicalTrials.Veeva

Menu

Randomized Trial of Regenexx Stem Cell Support Formula

R

Regenexx

Status

Completed

Conditions

Knee Osteoarthritis

Treatments

Dietary Supplement: Stem Cell Support Formula
Dietary Supplement: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT04661267
RGX2020-RCT02

Details and patient eligibility

About

Regenexx, LLC developed a nutritional supplement formula containing many components related to supporting healthy joints This oral, liquid supplement is intended to help improve joint and cartilage health while also increasing their joint function. The goal of this study is to measure changes in joint health and function for patients with knee OA taking this supplement for 2 months.

Full description

The study design is a double-blind, randomized, placebo-controlled multicenter study. Liquid Regenexx Stem Cell Support Formula compared to placebo control administered via oral application for 2 months to determine effect on knee function and pain in patients with knee OA.

Treatment group: Forty patients randomized to the treatment group will receive daily doses of stem cell support formula for 60 days. Patients will complete patient-reported outcome questionnaires at 1 month and 2 months.

Control group: Forty patients randomized to the control group will receive a daily doses of placebo stem cell support formula for 60 days. Patients will complete patient-reported outcome questionnaires at 1 month and 2 months.

Enrollment

80 patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

  1. Voluntary signature of the IRB approved Informed Consent

  2. Unilateral or bilateral osteoarthritic male or female ages 18-80

  3. Pain, swelling, and/or functional disability in the affected knee consistent with osteoarthritis in the knee joint

  4. Physical examination consistent with osteoarthritis in knee joint

  5. Kellgren-Lawrence grade 2 or 3 knee osteoarthritis and/or diagnostic MRI imaging of the affected knee showing osteoarthritis (i.e. chondral loss, fissuring, defect, bone marrow lesion, meniscus tear, synovial thickening, etc.)

  6. Minimum of 3/10 on NPS approximately 3 days per week

  7. Is independent, ambulatory, and can comply with all post-operative evaluations and visits

    Exclusion Criteria:

  8. Previously taken the Regenexx Stem Cell Support Formula

  9. Receiving active knee treatment or any knee injections of any type within 3 months prior to the study (steroids, biologics, etc)

  10. Knee surgery within 6 months prior to the study

  11. Currently taking or history of taking products that contain curcuminoid extract within the last 2 weeks

  12. Dependent on NSAIDs or acetaminophen for exercise or daily activities

  13. Currently taking or previously taken fish oil in the last 2 weeks

  14. Currently taking or previously taking MSM or glucosamine in the last 2 weeks

  15. Diabetic

  16. Inflammatory or auto-immune based joint diseases or other lower extremity pathology (e.g., rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis, polymyalgia, polymyositis, gout pseudogout)

  17. Quinolone or statin-induced myopathy/tendinopathy

  18. Severe neurogenic inflammation of the cutaneous nerves about the knee or thigh

  19. Contraindications for MRI

  20. Condition represents a worker's compensation case

  21. Currently involved in a health-related litigation procedure

  22. Is pregnant or breastfeeding

  23. Currently taking immunosuppressive medication

  24. Allergy or intolerance to study medication

  25. Use of chronic opioid

  26. Documented history of drug abuse within six months of treatment

  27. Blood clotting disorder, taking an anticoagulant or history of cardiovascular disease

  28. Has asthma

  29. History of prostate cancer

  1. Any other condition, that in the opinion of the investigator, that would preclude the patient from enrollment including current supplement use

Trial design

Primary purpose

Supportive Care

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

80 participants in 2 patient groups, including a placebo group

Supplement formula
Experimental group
Description:
Patients randomized to the experimental group will receive daily 1-ounce doses of stem cell support formula for 60 days. Patients will complete patient-reported outcome questionnaires at 1 month and 2 months.
Treatment:
Dietary Supplement: Stem Cell Support Formula
Placebo formula
Placebo Comparator group
Description:
Patients randomized to the control group will receive a daily 1-ounce doses of placebo stem cell support formula for 60 days. Patients will complete patient-reported outcome questionnaires at 1 month and 2 months.
Treatment:
Dietary Supplement: Placebo

Trial contacts and locations

2

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems